Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 4/2011

01-08-2011

Allergen-specific Immunotherapy in Atopic Eczema

Authors: Ulf Darsow, Ingeborg Forer, Johannes Ring

Published in: Current Allergy and Asthma Reports | Issue 4/2011

Login to get access

Abstract

Aeroallergens are relevant eliciting factors of allergic rhinoconjunctivitis and bronchial asthma but also of atopic eczema. The use of allergen-specific immunotherapy as in respiratory atopic diseases is controversial in patients with atopic eczema, but refined diagnostic methods to characterize subgroups of patients with relevant allergies and the results of smaller controlled studies give rise to new approaches in this field. This article reviews the theoretical problems and practical results associated with allergen-specific immunotherapy in atopic eczema.
Literature
1.
Ring J. Allergy in Practice. Berlin: Springer; 2005.
2.
Rajka G. Essential aspects of atopic dermatitis. Berlin: Springer; 1989.
3.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;114:146–8.
4.
Leung DYM, Rhodes AR, Geha RS, et al. Atopic dermatitis (atopic eczema). In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in General Medicine. 4th ed. New York: McGraw Hill; 1993. p. 1543–63.
5.
Morren MA, Przybilla B, Bamelis M, et al. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994;31:467–73.PubMedCrossRef
6.
Fukuda H, Imayama S, Okada T. Mite-free room (MFR) for the management of atopic dermatitis. Jpn J Allergol. 1991;40:626–32.
7.
Lau S, Ehnert B, Cremer B, et al. Häusliche Milbenallergenreduktion bei spezifisch sensibilisierten Patienten mit atopischem Ekzem. Allergo J. 1995;4:432–5.
8.
Sanda T, Yasue T, Oohashi M, Yasue A. Effectiveness of house dust-mite allergen avoidance with atopic dermatitis. J Allergy Clin Immunol. 1992;89:653–7.PubMedCrossRef
9.
Tan B, Weald D, Strickland I, Friedman P. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347:15–8.PubMedCrossRef
10.
Maurer D, Ebner C, Reininger B, et al. The high affinity IgE receptor mediates IgE-dependent allergen presentation. J Immunol. 1995;154:6285–90.PubMed
11.
Gondo A, Saeki N, Tokuda Y. Challenge reactions in atopic dermatitis after percutaneous entry of mite antigen. Br J Dermatol. 1986;115:485–93.PubMedCrossRef
12.
Bieber T. FCeRI on human Langerhans cells: a receptor in search of new functions. Immunol Today. 1994;15:52–3.PubMedCrossRef
13.
Bieber T, de la Salle C, Wollenberg A, et al. Constitutive expression of the high affinity receptor for IgE (FCeR1) on human Langerhans-cells. J Exp Med. 1992;175:1285–90.PubMedCrossRef
14.
Tanaka Y, Anan S, Yoshida H. Immunohistochemical studies in mite antigen-induced patch test sites in atopic dermatitis. J Derm Science. 1990;1:361–8.CrossRef
15.
Ramb-Lindhauer CH, Feldmann A, Rotte M, Neumann CH. Characterization of grass pollen reactive T-cell lines derived from lesional atopic skin. Arch Dermatol Res. 1991;283:71–6.PubMedCrossRef
16.
van Reijsen FC, Bruijnzeel-Koomen CAFM, Kalthoff FS, et al. Skin-derived aeroallergen-specific T-cell clones of TH2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol. 1992;90:184–92.PubMedCrossRef
17.
Adinoff A, Tellez P, Clark R. Atopic dermatitis and aeroallergen contact sensitivity. J Allergy Clin Immunol. 1988;81:736–42.PubMedCrossRef
18.
Maeda K, Yamamoto K, Tanaka Y, et al. House dust mite (HDM) antigen in naturally occurring lesions of atopic dermatitis (AD): The relationship between HDM antigen in the skin and HDM antigen-specific IgE antibody. J Derm Science. 1992;3:73–7.CrossRef
19.
Mitchell E, Chapman M, Pope F, et al. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet. 1982;I:127–30.CrossRef
20.
Darsow U, Vieluf D, Ring J. Atopy patch test with different vehicles and allergen concentrations—an approach to standardization. J Allergy Clin Immunol. 1995;95:677–84.PubMedCrossRef
21.
Darsow U, Vieluf D, Ring J. The atopy patch test: an increased rate of reactivity in patients who have an air-exposed pattern of atopic eczema. Br J Dermatol. 1996;135:182–6.PubMedCrossRef
22.
Darsow U, Behrendt H, Ring J. Gramineae pollen as trigger factors of atopic eczema: evaluation of diagnostic measures using the atopy patch test. Br J Dermatol. 1997;137:201–7.PubMedCrossRef
23.
Darsow U, Vieluf D, Berg B, et al. Dose response study of atopy patch test in children with atopic eczema. Pediatr Asthma Allergy Immunol. 1999;13:115–22.CrossRef
24.
Darsow U, Vieluf D. Ring J for the APT study group: evaluating the relevance of aeroallergen sensitization in atopic eczema using the tool “atopy patch test”: a randomized, double-blind multicenter study. J Am Acad Dermatol. 1999;40:187–93.CrossRef
25.
Fuchs E, Schadewaldt H. Die Einführung der Hyposensibilisierung in die Heufiebertherapie durch Leonard Noon (1878–1913) und John Freemann (1877–1962) im Jahre 1911. Allergo J. 1996;5:298–300.PubMed
26.
Elliot JR, Middleton MD, Charles E, Reed MD (eds.). Allergy: Principles and Practice. Mosby, St. Louis, 4th edition, 1993.
27.
Karl S, Ring J. Pro and contra of specific hyposensitization. Eur J Dermatol. 1999;9:325–31.PubMed
28.
Ring J. Spezifische Hyposensibilisierung bei atopischem Ekzem? Allergo J. 1993;2:1–2.
29.
Ring J, Przybilla B, Bongardts J. Safety of hyposensitization. In: Cortada Macias JM, editor. Proc Annual Meeting of the EAACI 1987. Madrid: Abelló; 1987. p. 130–8.
30.
Malling HJ, Weeke B. Immunotherapy. Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 1993;48 Suppl 14:9–35.CrossRef
31.
Willemse A, van den Brom W, Rijnberk A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assoc. 1984;184:1277–80.PubMed
32.
Saurat JH. Specific hyposensitization for atopic dermatitis: a new era? Dermatologica. 1991;182:71–2.PubMedCrossRef
33.
Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol. 1982;107:597–602.PubMedCrossRef
34.
Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440–6.PubMedCrossRef
35.
Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974;32:321–30.PubMed
36.
Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2:912–5.PubMedCrossRef
37.
Zachariae H, Cramers M, Herlin T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl. 1985;114:48–54.
38.
Galli E, Chini L, Nardi S, et al. Use of specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol. 1994;22:18–22.
39.
Mosca M, Albani-Rocchetti G, Vignini MA, et al. La vaccinoterapia sub-linguale nella dermatite atopica. G Ital Dermatol Venereol. 1993;128:79–83.
40.
Zwacka G, Glaser S, Rieger B. Therapeutische Erfahrungen mit Pangramin-SLIT im Vergleich zu einer subkutanen Immuntherapie und zur symptomatischen medikamentösen Behandlung bei Kindern mit Asthma bronchiale, Rhinokonjunktivitis und atopischer Dermatitis. Allergologie. 1996;19:580–92.
41.
Mastrandrea F. Immunotherapy in atopic dermatitis. Exp Opin Invest Drugs. 2001;10:1–15.CrossRef
42.
Mastrandrea F, Serio G, Minelli M. Specific sub-lingual immunotherapy in atopic dermatitis. Results of a 6-year follow up of 35 consecutive patients. Allergol Immunopathol. 2000;28:54–62.
43.
Noh G, Lee KJ. Pilot study of IFN-gamma-induced specific hyposensitization for house dust mites in atopic dermatitis: IFN-gamma-induced immune deviation as a new therapeutic concept for atopic dermatitis. Cytokine. 2000;12:472–6.PubMedCrossRef
44.
Leroy BP, Lachapelle JM, Somville MM, et al. Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis. Dermatologica. 1991;182:98–106.PubMedCrossRef
45.
Leroy BP, Boden G, Lachapelle JM, et al. A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. Am Acad Dermatol. 1993;28:232–9.CrossRef
46.
Werfel T, Breuer K, Ruéff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006;61:202–5.PubMedCrossRef
47.
Silny W, Czarnecka-Operacz M. Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Dermatitis. Ergebnisse einer placebokontrollierten Doppelblindstudie. Allergologie. 2006;29:171–83.
48.
Bousquet J, Lockey RF, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;53 Suppl 44:42.
49.
Kühr J, Brauburger J, Zielen S, he Omalizumab Rhinitis Study Group, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:274–80.CrossRef
50.
Bussmann C, Böckenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006;118:1292–8.PubMedCrossRef
51.
Di Prisco de Fuenmayor MC, Champion RH. Specific hyposensitization in atopic dermatitis. Br J Dermatol. 1979;101:697–700.PubMedCrossRef
52.
Chait I, Allkins V. Remission of life-long atopic dermatitis after hyposensitisation to house dust mite. Practitioner. 1985;229:609–12.PubMed
53.
Seidenari S, Mosca M, Taglietti M, et al. Specific hyposensitization in atopic dermatitis. Dermatologica. 1986;172:229.PubMedCrossRef
54.
Heijer A. Hyposensitization with aeroallergens in atopic eczema. Allergo J. 1993;2:3–7.
55.
Pacor ML, Biasi D, Maleknia T. The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic dermatitis. Recenti Prog Med. 1994;85:273–7.PubMed
56.
Michils A, Farber CM, Van Vooren JP, et al. Sustained benefit of interferon-alpha therapy and oral hyposensitization in severe atopic dermatitis. Br J Dermatol. 1994;130:134–5.PubMedCrossRef
57.
Trofimowicz A, Rzepecka E, Hofman J. Clinical effects of specific immunotherapy in children with atopic dermatitis. Rocz Akad Med Bialymst. 1995;40:414–22.PubMed
58.
Grewe M. Hyposensibilisierung bei atopischem Ekzem. Allergo J. 2000;9:351–3.
59.
Petrova SIu, Berzhets VM, Al’banova VI, et al. Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitization to house dust mites. Zh Mikrobiol Epidemiol Immunobiol. 2001;1:33–6.PubMed
60.
Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164–70.PubMedCrossRef
61.
Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy. 2007;37:1277–85.PubMedCrossRef
62.
Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007;23:2503–6.PubMedCrossRef
63.
Nahm DH, Lee ES, Park HJ, et al. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int Arch Allergy Immunol. 2008;146:235–40.PubMedCrossRef
Metadata
Title
Allergen-specific Immunotherapy in Atopic Eczema
Authors
Ulf Darsow
Ingeborg Forer
Johannes Ring
Publication date
01-08-2011
Publisher
Current Science Inc.
Published in
Current Allergy and Asthma Reports / Issue 4/2011
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0194-7

Other articles of this Issue 4/2011

Current Allergy and Asthma Reports 4/2011 Go to the issue

ReviewPaper

Immunologic Similarities between Selected Autoimmune Diseases and Peanut Allergy: Possible New Therapeutic Approaches

Clinical Trial Report

Forget the Worm—Does the Early Bird Avoid Developing Egg Allergy?

ReviewPaper

Dietary Immunomodulatory Factors in the Development of Immune Tolerance

Clinical Trial Report

Are We Still Missing the Point(s) When Managing Children with Food-Related Anaphylaxis?

ReviewPaper

New Therapeutics in C1INH Deficiency: A Review of Recent Studies and Advances

ReviewPaper

Update on the Diagnosis and Treatment of Shellfish Allergy